cached image

Joseph R. Bertino, M.D. - Publications

Weill Cornell Medical College, New York, NY, United States 
 1961-1987 Yale University School of Medicine, New Haven, CT 
Biochemistry, Molecular Biology, Pharmacology

120 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Shaik T, Rather GM, Bansal N, Minko T, Garbuzenko O, Szekely Z, Abali EE, Banerjee D, Kerrigan JE, Scotto KW, Bertino JR. Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer. Oncotarget. 9: 33249-33257. PMID 30279956 DOI: 10.18632/oncotarget.26064  0.56
2017 Kimani SG, Kumar S, Bansal N, Singh K, Kholodovych V, Comollo T, Peng Y, Kotenko SV, Sarafianos SG, Bertino JR, Welsh WJ, Birge RB. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Scientific Reports. 7: 43908. PMID 28272423 DOI: 10.1038/srep43908  0.36
2016 Tedeschi PM, Bansal N, Kerrigan JE, Abali EE, Scotto KW, Bertino JR. NAD+ Kinase as a Therapeutic Target in Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27582489 DOI: 10.1158/1078-0432.CCR-16-1129  0.36
2016 Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon YC, Zhong H, Medina D, Kerrigan J, Stein MN, ... ... Bertino J, et al. BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27307599 DOI: 10.1158/1078-0432.CCR-15-3107  0.36
2016 Tedeschi PM, Scotto KW, Kerrigan J, Bertino JR. MTHFD2- a new twist? Oncotarget. 7: 7368-9. PMID 26848977 DOI: 10.18632/oncotarget.7147  0.36
2016 Tedeschi PM, Scotto KW, Kerrigan J, Bertino JR. MTHFD2-a new twist? Oncotarget. 7: 7368-7369. DOI: 10.18632/oncotarget.7147  0.4
2015 Tedeschi PM, Lin H, Gounder M, Kerrigan JE, Abali EE, Scotto K, Bertino JR. Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy. Molecular Pharmacology. 88: 720-7. PMID 26219913 DOI: 10.1124/mol.114.096727  0.4
2015 Tedeschi PM, Vazquez A, Kerrigan JE, Bertino JR. Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development. Molecular Cancer Research : McR. 13: 1361-6. PMID 26101208 DOI: 10.1158/1541-7786.MCR-15-0117  0.4
2015 Bansal N, Mishra PJ, Stein M, DiPaola RS, Bertino JR. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Oncotarget. PMID 26036314  0.36
2015 DiFranco KM, Johnson-Farley N, Bertino JR, Elson D, Vega BA, Belinka BA, Kachlany SC. LFA-1-targeting Leukotoxin (LtxA; Leukothera®) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes. Leukemia Research. 39: 649-56. PMID 25850729 DOI: 10.1016/j.leukres.2015.03.010  0.4
2015 Bansal N, Farley NJ, Wu L, Lewis J, Youssoufian H, Bertino JR. Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling. Molecular Cancer Therapeutics. 14: 23-30. PMID 25381261 DOI: 10.1158/1535-7163.MCT-13-1040  0.36
2014 Munshi PN, Lubin M, Bertino JR. 6-thioguanine: a drug with unrealized potential for cancer therapy. The Oncologist. 19: 760-5. PMID 24928612 DOI: 10.1634/theoncologist.2014-0178  0.4
2014 Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR. A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts. Oncotarget. 5: 901-7. PMID 24658650  0.4
2014 Bansal N, Davis S, Tereshchenko I, Budak-Alpdogan T, Zhong H, Stein MN, Kim IY, Dipaola RS, Bertino JR, Sabaawy HE. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. The Prostate. 74: 187-200. PMID 24154958 DOI: 10.1002/pros.22740  0.4
2014 Hait WN, Rubin E, Bertino JR. Cancer Therapeutics The Molecular Basis of Cancer: Fourth Edition. 635-650.e1. DOI: 10.1016/B978-1-4557-4066-6.00046-9  0.36
2013 Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LLY, Qiu J, DiPaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, Vazquez A. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells Cell Death and Disease. 4. PMID 24157871 DOI: 10.1038/cddis.2013.393  0.4
2013 Xie X, Kerrigan JE, Minko T, Garbuzenko O, Lee KC, Scarborough A, Abali EE, Budak-Alpdogan T, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR. Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer. Cancer Biology & Therapy. 14: 742-51. PMID 23792570 DOI: 10.4161/cbt.25184  0.4
2013 Hsieh YC, Tedeschi P, Adebisi Lawal R, Banerjee D, Scotto K, Kerrigan JE, Lee KC, Johnson-Farley N, Bertino JR, Abali EE. Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs. Molecular Pharmacology. 83: 339-53. PMID 23197646 DOI: 10.1124/mol.112.080218  0.4
2012 Bertino JR, Lubin M, Johnson-Farley N, Chan WC, Goodell L, Bhagavathi S. Lack of expression of MTAP in uncommon T-Cell lymphomas Clinical Lymphoma, Myeloma and Leukemia. 12: 306-309. PMID 23040436 DOI: 10.1016/j.clml.2012.07.001  0.4
2012 Roussel B, Johnson-Farley N, Kerrigan JE, Scotto KW, Banerjee D, Felczak K, Pankiewicz KW, Gounder M, Lin H, Abali EE, Bertino JR. A second target of benzamide riboside: dihydrofolate reductase. Cancer Biology & Therapy. 13: 1290-8. PMID 22954684 DOI: 10.4161/cbt.21786  0.4
2012 Barboza NM, Medina DJ, Budak-Alpdogan T, Aracil M, Jimeno JM, Bertino JR, Banerjee D. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biology & Therapy. 13: 114-22. PMID 22336911 DOI: 10.4161/cbt.13.2.18876  0.56
2012 Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, ... ... Bertino JR, et al. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Molecular Cancer Therapeutics. 11: 775-83. PMID 22252602 DOI: 10.1158/1535-7163.MCT-11-0826  0.4
2012 Kerrigan JE, Abali EE, Bertino JR. Recent progress in molecular dynamics simulations of dihydrofolate reductase Current Enzyme Inhibition. 8: 140-149. DOI: 10.2174/157340812800793264  0.4
2011 Bertino JR, Waud WR, Parker WB, Lubin M. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies. Cancer Biology & Therapy. 11: 627-32. PMID 21301207 DOI: 10.4161/cbt.11.7.14948  0.4
2011 Moroz MA, Kochetkov T, Cai S, Wu J, Shamis M, Nair J, de Stanchina E, Serganova I, Schwartz GK, Banerjee D, Bertino JR, Blasberg RG. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1099-110. PMID 21245090 DOI: 10.1158/1078-0432.CCR-10-1430  0.56
2010 Peters R, Wolf MJ, van den Broek M, Nuvolone M, Dannenmann S, Stieger B, Rapold R, Konrad D, Rubin A, Bertino JR, Aguzzi A, Heikenwalder M, Knuth AK. Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture. Plos One. 5: e15689. PMID 21209896 DOI: 10.1371/journal.pone.0015689  0.4
2009 Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, Merlino G, Ju J, Bertino JR. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. Plos One. 4: e8445. PMID 20041160 DOI: 10.1371/journal.pone.0008445  0.56
2009 Mishra PJ, Menon LG, Mishra PJ, Mayer-Kuckuk P, Bertino JR, Banerjee D. Translational modulation of proteins expressed from bicistronic vectors. Molecular Imaging. 8: 305-18. PMID 20003889  0.56
2009 Levitt MJ, Gharibo M, Strair R, Schaar D, Rubin A, Bertino JR. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate. Journal of Chemotherapy (Florence, Italy). 21: 434-8. PMID 19622463 DOI: 10.1179/joc.2009.21.4.434  0.36
2009 Hsieh YC, Skacel NE, Bansal N, Scotto KW, Banerjee D, Bertino JR, Abali EE. Species-specific differences in translational regulation of dihydrofolate reductase. Molecular Pharmacology. 76: 723-33. PMID 19570950 DOI: 10.1124/mol.109.055772  0.36
2009 Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, Pizzorno G, Cheng YC, Kemeny N, Bertino JR, Banerjee D. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Molecular Cancer Therapeutics. 8: 1037-44. PMID 19383847 DOI: 10.1158/1535-7163.MCT-08-0716  0.56
2009 Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Molecular Cancer Therapeutics. 8: 1045-54. PMID 19383845 DOI: 10.1158/1535-7163.MCT-08-0717  0.56
2009 Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Molecular targets for epigenetic therapy of cancer. Current Pharmaceutical Biotechnology. 10: 161-5. PMID 19199948  0.56
2008 Yang R, Li WW, Hoang BH, Kim H, Banerjee D, Kheradpour A, Healey JH, Meyers PA, Bertino JR, Gorlick R. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. Bmc Cancer. 8: 124. PMID 18452618 DOI: 10.1186/1471-2407-8-124  0.56
2008 Mishra PJ, Mishra PJ, Banerjee D, Bertino JR. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Cell Cycle (Georgetown, Tex.). 7: 853-8. PMID 18414050 DOI: 10.4161/cc.7.7.5666  0.56
2007 Bertino JR, Banerjee D, Mishra PJ. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics. 8: 1625-7. PMID 18085993 DOI: 10.2217/14622416.8.12.1625  0.56
2007 Humeniuk R, Menon LG, Mishra PJ, Saydam G, Longo-Sorbello GSA, Elisseyeff Y, Lewis LD, Aracil M, Jimeno J, Bertino JR, Banerjee D. Aplidin synergizes with cytosine arabinoside: Functional relevance of mitochondria in Aplidin-induced cytotoxicity Leukemia. 21: 2399-2405. PMID 17713546 DOI: 10.1038/sj.leu.2404911  0.36
2007 Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proceedings of the National Academy of Sciences of the United States of America. 104: 13513-8. PMID 17686970 DOI: 10.1073/pnas.0706217104  0.56
2006 Russo AJ, Magro PG, Hu Z, Li WW, Peters R, Mandola J, Banerjee D, Bertino JR. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Research. 66: 7253-60. PMID 16849574 DOI: 10.1158/0008-5472.CAN-05-3725  0.56
2006 Mayer-Kuckuk P, Doubrovin M, Bidaut L, Budak-Alpdogan T, Cai S, Hubbard V, Alpdogan O, van den Brink M, Bertino JR, Blasberg RG, Banerjee D, Gelovani J. Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells. Cell Transplantation. 15: 75-82. PMID 16700332  0.56
2006 Huang X, Metaxas DN, Menon LG, Mayer-Kuckuk P, Bertino JR, Banerjee D. Recovering 3D tumor locations from 2D bioluminescence images and registration with CT images Proceedings of Spie - the International Society For Optical Engineering. 6081. DOI: 10.1117/12.647662  0.36
2005 Budak-Alpdogan T, Banerjee D, Bertino JR. Hematopoietic stem cell gene therapy with drug resistance genes: an update. Cancer Gene Therapy. 12: 849-63. PMID 16037821 DOI: 10.1038/sj.cgt.7700866  0.56
2005 Mayer-Kuckuk P, Gade TP, Buchanan IM, Doubrovin M, Ageyeva L, Bertino JR, Boskey AL, Blasberg RG, Koutcher JA, Banerjee D. High-resolution imaging of bone precursor cells within the intact bone marrow cavity of living mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 33-41. PMID 15963918 DOI: 10.1016/j.ymthe.2005.02.018  0.36
2005 Skacel N, Menon LG, Mishra PJ, Peters R, Banerjee D, Bertino JR, Abali EE. Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate Treatment. The Journal of Biological Chemistry. 280: 22721-31. PMID 15817466 DOI: 10.1074/jbc.M500277200  0.56
2004 Capiaux GM, Budak-Alpdogan T, Alpdogan O, Bornmann W, Takebe N, Banerjee D, Maley F, Bertino JR. Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene Cancer Gene Therapy. 11: 767-773. PMID 15359285 DOI: 10.1038/sj.cgt.7700683  0.36
2004 Budak-Alpdogan T, Alpdogan O, Banerjee D, Wang E, Moore MA, Bertino JR. Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 574-84. PMID 15336657 DOI: 10.1016/j.ymthe.2004.06.115  0.56
2004 Magro PG, Russo AJ, Li WW, Banerjee D, Bertino JR. p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53. Cancer Research. 64: 4338-45. PMID 15205349 DOI: 10.1158/0008-5472.CAN-03-1045  0.56
2004 Mayer-Kuckuk P, Menon LG, Blasberg RG, Bertino JR, Banerjee D. Role of reporter gene imaging in molecular and cellular biology. Biological Chemistry. 385: 353-61. PMID 15195994 DOI: 10.1515/BC.2004.039  0.56
2004 Iwamoto M, Banerjee D, Menon LG, Jurkiewicz A, Rao PH, Kemeny NE, Fong Y, Jhanwar SC, Gorlick R, Bertino JR. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biology & Therapy. 3: 395-9. PMID 14726656  0.56
2003 Levy AS, Sather HN, Steinherz PG, Sowers R, La M, Moscow JA, Gaynon PS, Uckun FM, Bertino JR, Gorlick R. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. Journal of Pediatric Hematology/Oncology. 25: 688-95. PMID 12972803 DOI: 10.1097/00043426-200309000-00004  0.36
2003 Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR, Gorlick R. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Molecular Cancer Therapeutics. 2: 535-41. PMID 12813132  0.56
2003 Capiaux GM, Budak-Alpdogan T, Takebe N, Mayer-Kuckuk P, Banerjee D, Maley F, Bertino JR. Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Human Gene Therapy. 14: 435-46. PMID 12691609 DOI: 10.1089/104303403321467207  0.68
2003 Bertino JR, Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1235-9. PMID 12684389  0.56
2003 Mayer-Kuckuk P, Doubrovin M, Gusani NJ, Gade T, Balatoni J, Akhurst T, Finn R, Fong Y, Koutcher JA, Larson S, Blasberg R, Tjuvajev JG, Bertino JR, Banerjee D. Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats. European Journal of Nuclear Medicine and Molecular Imaging. 30: 1281-91. PMID 12664136 DOI: 10.1007/s00259-003-1143-z  0.36
2003 Yang R, Sowers R, Mazza B, Healey JH, Huvos A, Grier H, Bernstein M, Beardsley GP, Krailo MD, Devidas M, Bertino JR, Meyers PA, Gorlick R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples Clinical Cancer Research. 9: 837-844. PMID 12576457  0.36
2002 Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Research. 62: 6909-15. PMID 12460906  0.36
2002 Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases Cancer Research. 62: 4244-4255. PMID 12154026  0.36
2002 Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochimica Et Biophysica Acta. 1587: 164-73. PMID 12084458  0.56
2002 Mayer-Kuckuk P, Banerjee D, Kemeny N, Fong Y, Bertino JR. Molecular therapies for colorectal cancer metastatic to the liver. Molecular Therapy : the Journal of the American Society of Gene Therapy. 5: 492-500. PMID 11991739 DOI: 10.1006/mthe.2002.0596  0.56
2002 Banerjee D, Bertino JR. Myeloprotection with drug-resistance genes. The Lancet. Oncology. 3: 154-8. PMID 11902501  0.56
2002 Mayer-Kuckuk P, Banerjee D, Malhotra S, Doubrovin M, Iwamoto M, Akhurst T, Balatoni J, Bornmann W, Finn R, Larson S, Fong Y, Gelovani Tjuvajev J, Blasberg R, Bertino JR. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. Proceedings of the National Academy of Sciences of the United States of America. 99: 3400-5. PMID 11891321 DOI: 10.1073/pnas.062036899  0.56
2001 Sapse AM, Capiaux GM, Bertino JR. Examination of the reduced affinity of the thymidylate synthase G52S mutation for FdUMP by ab initio and semi-empirical studies. Molecular Medicine (Cambridge, Mass.). 7: 200-4. PMID 11471557  0.68
2001 Takebe N, Zhao SC, Adhikari D, Mineishi S, Sadelain M, Hilton J, Colvin M, Banerjee D, Bertino JR. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Molecular Therapy : the Journal of the American Society of Gene Therapy. 3: 88-96. PMID 11162315 DOI: 10.1006/mthe.2000.0236  0.36
2000 Levy AS, Meyers P, Kellick M, Gorlick R, Tong W, Bertino JR. Acute stroke-like encephalopathy associated with high-dose methotrexate impurities [2] Journal of Pediatric Hematology/Oncology. 22: 360-362. PMID 10959910 DOI: 10.1097/00043426-200007000-00017  0.36
2000 Ural AU, Takebe N, Adhikari D, Ercikan-Abali E, Banerjee D, Barakat R, Bertino JR. Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene. Gynecologic Oncology. 76: 305-10. PMID 10684701 DOI: 10.1006/gyno.1999.5707  0.56
1999 Casper ES, Schwartz GM, Leung D, Sugarman A, Bertino JR. Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma. Sarcoma. 3: 121-7. PMID 18521274 DOI: 10.1080/13577149977758  0.36
1999 Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 3776-85. PMID 10577849 DOI: 10.1200/JCO.1999.17.12.3776  0.4
1999 Hochhauser D, Valkov NI, Gump JL, Wei I, O'Hare C, Hartley J, Fan J, Bertino JR, Banerjee D, Sullivan DM. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines. Journal of Cellular Biochemistry. 75: 245-57. PMID 10502297 DOI: 10.1002/(SICI)1097-4644(19991101)75:2<245::AID-JCB7>3.0.CO;2-G  0.56
1999 Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ, Fong Y. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 13: 1325-34. PMID 10428757  0.36
1998 Casper ES, Waltzman RJ, Schwartz GK, Sugarman A, Pfister D, Ilson D, Woodruff J, Leung D, Bertino JR. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Investigation. 16: 442-6. PMID 9774950 DOI: 10.3109/07357909809011697  0.36
1998 Tong Y, Liu-Chen X, Ercikan-Abali EA, Capiaux GM, Zhao SC, Banerjee D, Bertino JR. Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. The Journal of Biological Chemistry. 273: 11611-8. PMID 9565579  0.68
1998 Gorlick R, Metzger R, Danenberg KD, Salonga D, Miles JS, Longo GS, Fu J, Banerjee D, Klimstra D, Jhanwar S, Danenberg PV, Kemeny N, Bertino JR. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 1465-9. PMID 9552053 DOI: 10.1200/JCO.1998.16.4.1465  0.36
1997 Ercikan-Abali EA, Banerjee D, Waltham MC, Skacel N, Scotto KW, Bertino JR. Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region Biochemistry. 36: 12317-12322. PMID 9315871 DOI: 10.1021/bi971026e  0.36
1997 Fan J, Banerjee D, Stambrook PJ, Bertino JR. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras Biochemical Pharmacology. 53: 1203-1209. PMID 9175726 DOI: 10.1016/S0006-2952(97)00101-9  0.36
1997 Waltham MC, Li WW, Gritsman H, Tong WP, Bertino JR. gamma-Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists. Molecular Pharmacology. 51: 825-32. PMID 9145921 DOI: 10.1124/mol.51.5.825  0.56
1997 Rosowsky A, Forsch RA, Queener SF, Bertino JR. Synthesis of 2,4-diaminopteridines with bulky lipophilic groups at the 6-position as inhibitors of Pneumocystis carinii, Toxoplasma gondii, and mammalian dihydrofolate reductase Pteridines. 8: 173-187.  0.36
1995 Lenz HJ, Danenberg KD, Schnieders B, Banerjee D, Bertino JR, Leichman L, Danenberg PV. Identification of mutations by RNA conformational polymorphism 'bar code' analysis Genomics. 30: 120-122. PMID 8595893 DOI: 10.1006/geno.1995.0024  0.4
1995 Rosowsky A, Mota CE, Queener SF, Waltham M, Ercikan-Abali E, Bertino JR. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii Journal of Medicinal Chemistry. 38: 745-752. PMID 7877140  0.36
1995 Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, Bertino JR, Wahl GM. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 92: 5436-40. PMID 7777526 DOI: 10.1073/pnas.92.12.5436  0.36
1994 Horikoshi T, Lenz HJ, Danenberg K, Koch OM, Bertino JR, Danenberg PV. Quantitative determination of the ratio of mutated to normal ras genes in the blood of leukemia patients by allele-specific PCR Leukemia Research. 18: 693-702. PMID 7934145 DOI: 10.1016/0145-2126(94)90069-8  0.36
1993 Casper ES, Christman KL, Schwartz GK, Johnson B, Brennan MF, Bertino JR. Edatrexate in patients with soft tissue sarcoma: Activity in malignant fibrous histiocytoma Cancer. 72: 766-770. PMID 8392904  0.36
1993 Ercikan E, Banerjee D, Waltham M, Schnieders B, Scotto KW, Bertino JR. Translational regulation of the synthesis of dihydrofolate reductase Advances in Experimental Medicine and Biology. 338: 537-540. PMID 8304175  0.36
1993 Wienecke R, Volkenandt M, Koch O, Neubert U, McNutt NS, Danenberg PV, Bertino JR. Rapid and sensitive molecular subtyping of microorganisms in clinical specimens. Lancet (London, England). 341: 830-1. PMID 7681136 DOI: 10.1016/0140-6736(93)90606-H  0.4
1992 Li M, Hantzopoulos PA, Banerjee D, Zhao SC, Schweitzer BI, Gilboa E, Bertino JR. Comparison of the expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors Human Gene Therapy. 3: 381-390. PMID 1525211 DOI: 10.1089/hum.1992.3.4-381  0.36
1992 Danenberg PV, Horikoshi T, Volkenandt M, Danenberg K, Lenz Hj, Shea LCC, Dicker AP, Simoneau A, Jones PA, Bertino JR. Detection of point mutations in human DNA by analysis of RNA conformation polymorphism(s) Nucleic Acids Research. 20: 573-579. PMID 1371351 DOI: 10.1093/nar/20.3.573  0.4
1992 Sapse AM, Schweitzer BS, Dicker AP, Bertino JR, Frecer V. Ab initio studies of aromatic-aromatic and aromatic-polar interactions in the binding of substrate and inhibitor to dihydrofolate reductase International Journal of Peptide and Protein Research. 39: 18-23. PMID 1299221 DOI: 10.1111/J.1399-3011.1992.TB01550.X  0.4
1991 Lin JT, Bertino JR. Clinical science review: Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties Cancer Investigation. 9: 159-172. PMID 1830825 DOI: 10.3109/07357909109044227  0.36
1989 Lin JT, Bertino JR. Current status of trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties Cancer Treatment and Research. 42: 79-95. PMID 2577109 DOI: 10.1007/978-1-4613-1747-0_5  0.4
1987 Lin JT, Bertino JR. Trimetrexate: A second generation folate antagonist in clinical trial Journal of Clinical Oncology. 5: 2032-2040. PMID 2960788 DOI: 10.1200/JCO.1987.5.12.2032  0.36
1987 Mini E, Mazzei T, Coronnello M, Criscuoli L, Gualtieri M, Periti P, Bertino JR. Effects of 5-methyltetrahydrofolate on the activity of fluoropyrimidines against human leukemia (CCRF-CEM) cells. Biochemical Pharmacology. 36: 2905-11. PMID 2958010 DOI: 10.1016/0006-2952(87)90201-2  0.4
1986 Koletsky AJ, Bertino JR, Farber LR, Prosnitz LR, Kapp DS, Fischer D, Portlock CS. Second Neoplasms in Patients With Hodgkin's Disease Following Combined Modality Therapy-The Yale Experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 4: 817. PMID 28423288 DOI: 10.1200/JCO.1986.4.5.817  0.4
1984 McGuire JJ, Hsieh P, Bertino JR. Enzymatic synthesis of polyglutamate derivatives of 7-hydroxymethotrexate Biochemical Pharmacology. 33: 1355-1361. PMID 6201178 DOI: 10.1016/0006-2952(84)90192-8  0.4
1984 Bertino JR, Kowal CD, Klein ME, Dombrowski J, Mini E. The potential for chemotherapy and hyperthermia. Frontiers of Radiation Therapy and Oncology. 18: 162-70. PMID 6200385 DOI: 10.1159/000429211  0.4
1983 Srimatkandada S, Medina WD, Cashmore AR, Whyte W, Engel D, Moroson BA, Franco CT, Dube SK, Bertino JR. Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexate. Biochemistry. 22: 5774-81. PMID 6661412 DOI: 10.1021/bi00294a015  0.4
1983 McGuire JJ, Hsieh P, Coward JK, Bertino JR. In vitro methotrexate polyglutamate synthesis by rat liver folylpolyglutamate synthetase and inhibition by bromosulfophthalein. Advances in Experimental Medicine and Biology. 163: 199-214. PMID 6193685  0.36
1982 Newcomer LN, Cadman EC, Prosnitz LR, Farber LR, Bertino JR. Splenectomy in Hodgkin's disease: No therapeutic benefit American Journal of Clinical Oncology: Cancer Clinical Trials. 5: 393-397. PMID 7113962 DOI: 10.1097/00000421-198208000-00008  0.4
1982 Newcomer LN, Silverstein MB, Cadman EC, Farber LR, Bertino JR, Prosnitz LR. Bone involvement in Hodgkin's disease Cancer. 49: 338-342. PMID 7053832 DOI: 10.1002/1097-0142(19820115)49:2<338::AID-CNCR2820490221>3.0.CO;2-I  0.4
1982 Newcomer LN, Nerenberg MI, Cadman EC, Waldron JA, Farber LR, Bertino JR. The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapy Cancer. 50: 439-443. PMID 7046901 DOI: 10.1002/1097-0142(19820801)50:3<439::AID-CNCR2820500310>3.0.CO;2-P  0.4
1981 Scheer DI, Srimatkandada S, Kamen BA, Dube S, Bertino JR. Organization of the methotrexate resistant mouse L5178YR dihydrofolate reductase gene and transformation of human HCT-8 cells by this gene Hamatologie Und Bluttransfusion. 26: 171-174. PMID 6947931 DOI: 10.1007/978-3-642-67984-1_28  0.4
1980 Kim KH, Dietrich SW, Hansch C, Dolnick BJ, Bertino JR. Inhibition of dihydrofolate reductase. 3. 4.6-Diamino-1,2-dihydro-2,2-dimethyl-1-(2-substituted-phenyl)-s-triazine inhibition of bovine liver and mouse tumor enzymes. Journal of Medicinal Chemistry. 23: 1248-51. PMID 7452676 DOI: 10.1021/jm00185a022  0.4
1980 Cashmore AR, Dreyer RN, Horváth C, Knipe JO, Coward JK, Bertino JR. Separation of pteroyl-oligo-gamma-L-glutamates by high-performance liquid-chromatography. Methods in Enzymology. 66: 459-68. PMID 7374486 DOI: 10.1016/0076-6879(80)66489-1  0.4
1979 Dolnick BJ, Berenson RJ, Bertino JR, Kaufman RJ, Nunberg JH, Schimke RT. Correlation of dihydrofolate reductase elevation with gene amplification in a homogeneously staining chromosomal region in L5178Y cells. The Journal of Cell Biology. 83: 394-402. PMID 500787 DOI: 10.1083/jcb.83.2.394  0.36
1979 Bush BT, Frenz JH, Melander WR, Horváth C, Cashmore AR, Dryer RN, Knipe JO, Coward JK, Bertino JR. Retention behavior of pteroyl-oligo-γ-l-glutamates in reversed-phase chromatography Journal of Chromatography A. 168: 343-353. DOI: 10.1016/0021-9673(79)80004-7  0.4
1978 Schimke RT, Alt FW, Kellems RE, Kaufman RJ, Bertino JR. Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells. Cold Spring Harbor Symposia On Quantitative Biology. 42: 649-57. PMID 277312  0.4
1977 Lindquist CA, Cadman EC, Bertino JR. A fluorometric assay for dihydrofolate reductase. Analytical Biochemistry. 83: 20-5. PMID 920937 DOI: 10.1016/0003-2697(77)90504-8  0.48
1977 Cadman EC, Lunberg WB, Bertino JR. Hyperphosphatermia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. The American Journal of Medicine. 62: 283-90. PMID 835606 DOI: 10.1016/0002-9343(77)90324-2  0.68
1977 Gupta SV, Greenfield NJ, Poe M, Makulu DR, Williams MN, Moroson BA, Bertino JR. Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification by affinity chromatography and ultraviolet difference spectrophotometric and circular dichroic studies. Biochemistry. 16: 3073-9. PMID 19040 DOI: 10.1021/bi00633a005  0.4
1976 Mitchell MS, Gifford RH, Bertino JR, Kenney JD, Malawista SE. The treatment of disseminated vasculitis with methotrexate. Inflammation. 1: 285-95. PMID 24194451 DOI: 10.1007/BF00917868  0.4
1976 Bertino JR, Coward JK, Cashmore A, Chello P, Panichajakul S, Horvath CG, Stout RW. Polyglutamate forms of folate: natural occurrence and role as substrates in mammalian cells. Biochemical Society Transactions. 4: 853-6. PMID 1069685  0.36
1976 Stout RW, Cashmore AR, Coward JK, Horvath CG, Bertino JR. Separation of substituted pteroyl monoglutamates and pteroyl oligo-γ-l-glutamates by high pressure liquid chromatography Analytical Biochemistry. 71: 119-124. DOI: 10.1016/0003-2697(76)90017-8  0.36
1975 Coward JK, Chello PL, Cashmore AR, Parameswaran KN, DeAngelis LM, Bertino JR. 5-methyl-5,6,7,8-tetrahydropteroyl oligo-gamma-L-glutamates: synthesis and kinetic studies with methionine synthetase from bovine brain. Biochemistry. 14: 1548-52. PMID 1125187  0.4
1974 Coward JK, Parameswaran KN, Cashmore AR, Bertino JR. 7,8-Dihydropteroyl oligo-gamma-L-glutamates: synthesis and kinetic studies with purified dihydrofolate reductase from mammalian sources. Biochemistry. 13: 3899-903. PMID 4528865  0.4
1972 Chello PL, Cashmore AR, Jacobs SA, Bertino JR. Improved purification of tetrahydrofolate dehydrogenase from L1210 leukemia by affinity chromatography. Biochimica Et Biophysica Acta. 268: 30-4. PMID 5018279 DOI: 10.1016/0005-2744(72)90193-3  0.4
1971 Bertino JR, O'Brien P, McCullough JL. Inhibition of growth of leukemia cells by enzymic folate depletion Science. 172: 161-162. PMID 5313376 DOI: 10.1126/science.172.3979.161  0.36
1971 Jacobs SA, D'Urso-Scott M, Bertino JR. Some biochemical and pharmacologic properties of amethopterin-albumin. Annals of the New York Academy of Sciences. 186: 284-6. PMID 5289421 DOI: 10.1111/j.1749-6632.1971.tb46982.x  0.4
1971 Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C, Peterson RG, Handschumacher RE. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Annals of Internal Medicine. 74: 893-901. PMID 5281051  0.4
1971 McCullough JL, Bertino JR. Dihydrofolate reductase from mouse liver and spleen. Purification, properties and inhibition by substituted 2,4-diaminopyrimidines and 4,6-diaminotriazines Biochemical Pharmacology. 20: 561-574. PMID 4402459 DOI: 10.1016/0006-2952(71)90143-2  0.36
1966 Johns DG, Sartorelli AC, Bertino JR, Iannotti AT, Booth BA, Welch AD. Enzymic hydroxylation of 5-fluoropyrimidines by aldehyde oxidase and xanthine oxidase Biochemical Pharmacology. 15: 400-403. PMID 5911552 DOI: 10.1016/0006-2952(66)90314-5  0.36
1963 Huennekens FM, Bertino JR, Silber R, Gabrio BW. Antimetabolites in the chemotherapy of leukemia Experimental Cell Research. 9: 441-461. PMID 14046245  0.36
Show low-probability matches.